Scientific presentations
Analytics show super spenders account for nearly 10% of total drug spend
Studies on members with drug costs over $250,000 yield predictive modeling data
February 21, 2021
Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
Ongoing studies using integrated benefits data on drug super spenders – members with total drug costs over $250,000 a year – provide predictive modeling data that can help manage outcomes and control costs
For many specialty conditions, nearly 90% of the total cost of care can come from drugs. That’s why Prime’s expertise at drug management is so important in controlling costs.
This study categorized and described trends in the medical conditions accounting for these member’s extraordinary drug expense.
This study contributes to Prime’s understanding of which drugs, conditions, and other factors can result in drug super spenders. It contributes to Prime’s ability to identify such members early by predictive modeling, and strategies to improve management of high cost specialty drugs. Integrated pharmacy claims analysis helps to confirm effectiveness of clinical programs and to identify additional opportunities.
Related research
Scientific presentations
August 1, 2021
Prime’s analytics uncovers the hidden ups and downs behind the flat drug trend for MS DMDs
Insights from integrated medical and pharmacy claims show a big upswing in one…
Scientific presentations
June 21, 2021
Break autoimmune (AI) into indication-specific info for actionable strategy
Prime uses integrated medical and pharmacy data and breaks down largest drug category…
Scientific presentations
April 21, 2021
Prime links changes in adherence rates with total cost of care
Prime’s unique study of Medicare Advantage members uses integrated benefits data to show…